Johnson & Johnson / Numab Therapeutics AG (Yellow Jersey Therapeutics)

Moderate-to-severe atopic dermatitis (AD)

6.6M US cases/yr · $14.0B Global AD therapeutics market 2024 (branded biologics + JAKs + topicals) · 14000 Dupixent global net sales 2024 (USD MM, all indications, Sanofi/Regeneron)

Disease Overview

Atopic dermatitis is a chronic, relapsing, pruritic inflammatory skin disease driven primarily by Type 2 immune dysregulation (IL-4, IL-13, IL-31, TSLP) overlaid on epidermal barrier dysfunction. The National Eczema Association and NIH estimate AD affects 16.5 million US adults, with approximately 6.6 million classified as moderate-to-severe based on self-reported impact and Patient-Oriented Eczema Measure scores; pediatric prevalence is an additional ~9.6 million. The disease carries substantial quality-of-life burden including sleep disturbance from itch (IL-31 driven), skin infections, and increased risk of asthma, food allergy, and anxiety/depression. Topical corticosteroids, topical calcineurin inhibitors (tacrolimus, pimecrolimus), and topical PDE4 inhibitors (crisaborole, roflumilast) remain first-line but are inadequate for moderate-to-severe patients. Systemic options have exploded since 2017: Dupixent (dupilumab, IL-4Rα) set the biologic standard, followed by Adbry (tralokinumab, IL-13), Ebglyss (lebrikizumab, IL-13), nemolizumab (IL-31RA), and oral JAK inhibitors (Rinvoq, Cibinqo). Despite this, roughly 30-40% of Dupixent-treated patients fail to achieve EASI-75, and itch reduction often lags lesional clearance, creating an itch-specific unmet need that IL-31 blockade directly addresses.

Competitive Landscape

The AD biologic landscape is crowded but still growing. IL-4Rα blockade: Dupixent (dupilumab, Sanofi/Regeneron) — gold-standard approved 2017 with approximately $14B 2024 sales across AD/asthma/EoE/COPD. IL-13 blockade: Adbry (tralokinumab, LEO Pharma) and Ebglyss (lebrikizumab, Eli Lilly, approved Sep 2024) — differentiated tolerability with monthly maintenance. IL-31RA blockade: nemolizumab (Nemluvio, Galderma, approved Aug 2024 for prurigo nodularis, AD approval Dec 2024) — itch-specific mechanism. OX40/OX40L: rocatinlimab (Amgen/Kyowa Kirin) and amlitelimab (Sanofi from Kymab) — Phase 3. Oral JAKs: Rinvoq (upadacitinib, AbbVie), Cibinqo (abrocitinib, Pfizer) — rapid onset but boxed-warning safety concerns. Numab's NM26 is positioned as a first-in-class IL-4Rα/IL-31 bispecific combining the dupilumab-validated IL-4/IL-13 axis with IL-31 itch blockade in a single subcutaneous agent — potentially enabling less frequent dosing and addressing residual itch burden in Dupixent-inadequate responders.